2024-512172-35-00招募中2 期
Impact of CHOlinergic Stimulation on COgnitive and MOtor Functions and Brain Activity in Elderly Volunteers (CHOCOMO) - a randomised, placebo-controlled trial
Carl Von Ossietzky Universitaet Oldenburg1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年7月16日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Dual-task costs (DTC): calculated as the difference between the scores of the dual-task and single-task performances and measured as reaction time (ms) in the cognitive task and motor pedaling speed (ms) in the motor task after donepezil or placebo administration, respectively, at V1 and 2
研究概览
简要总结
To compare the effects of an increase of acetylcholine levels by administration of a single 5 mg acute dose of the cholinerase inhibitor donepezil versus placebo on cognitive-motor Dual-task costs in the elderly
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers
- •Male or female aged ≥ 50 years without upper age limit
- •Right-handed
- •BMI 18 - 32 kg/m2
- •Suitable for MRI
- •Written informed consent obtained according to international guidelines and local laws
- •Capacity to understand the nature, significance and consequences of the trial and the trial related procedures and to comply with them
排除标准
- •Known clinically significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, urological, immunologic, neurologic, oncologic or psychiatric disease or other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results
- •Planned surgery within the study and follow-up period
- •Metal implants and/or components on the body that cannot be removed
- •Participation in any other interventional clinical trial within the last 30 days before the start of this trial and/or simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed
- •Previous participation in this trial
- •Known abuse of medication, drugs or alcohol
- •Person who is in a relationship of dependence/employment with the Sponsor or the Principle Investigator
- •Person who lack of sufficient communication skills in the German language
- •Person who is institutionalised by court or official order
- •Current or planned pregnancy, nursing period
- •Failure to use one of the following safe methods of contraception: female condoms, diaphragm or coil, each used in combination with spermicides; intra-uterine device; hormonal contraception in combination with a mechanical method of contraception
- •Known QTc prolongation and/or family history of QTc prolongation
- •Known electrolyte imbalance (hypokalemia, hypomagnesemia)
- •Known claustrophobia
- •Known defective vision of > +/- 6 dioptres if not corrected by contact lenses
- •Known hypersensitivity to the active substances, piperidine derivatives or any of the excipients of the IMP / Placebo according to the SmPc
- •Current use and/or use up to 30 days prior to study entry of:
- •Substances that influence the QTc interval according to SmPC;
- •Non-steroidal anti-inflammatory drugs (NSAIDs) on a regular long-term basis;
- •Donepezil hydrochloride or related drugs with anti- and cholinergic activity and neuromuscular blocking agents according to SmPc;
- •CYP3A4 and 2D6 inhibitory and inducing substances according to SmPc: chinidin, itraconazole, erythromycin, fluoxetine, rifampicin, phenytoin, carbamazepine, systemic use of ketoconazole;
- •Beta blockers
- •After at least 3 minutes of rest in a sitting position, subjects should be excluded from the study if they have the following vital signs at screening:
- •systolic blood pressure outside the range of 90-145 mmHg, or
- •diastolic blood pressure outside the range of 50-90 mmHg, or
- •resting heart rate outside the range of 40-100 beats per minute
- •Abnormal ECG values during screening
结局指标
主要结局
Dual-task costs (DTC): calculated as the difference between the scores of the dual-task and single-task performances and measured as reaction time (ms) in the cognitive task and motor pedaling speed (ms) in the motor task after donepezil or placebo administration, respectively, at V1 and 2
Dual-task costs (DTC): calculated as the difference between the scores of the dual-task and single-task performances and measured as reaction time (ms) in the cognitive task and motor pedaling speed (ms) in the motor task after donepezil or placebo administration, respectively, at V1 and 2
次要结局
- Neuronal activity: measured after donepezil or placebo administration, respectively, by fMRI during task performance at visit 1 and 2
- Relative cognitive and motor performances in other neuropsychological tests: 1. measured by reaction times (ms) and % correct responses in the sub-tests of TAP-M test battery and 2. measured by time (s) conducting the TUG-test variant, both after donepezil or placebo administration, respectively, at V1 and 2
研究者
Coordinating Scientist
Scientific
Carl Von Ossietzky Universitaet Oldenburg
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Impact of CHOlinergic Stimulation on COgnitive and MOtor Functions and Brain Activity in Elderly Volunteers (CHOCOMO) - a randomised, placebo-controlled trialCTIS2024-512172-35-00Carl Von Ossietzky Universitaet Oldenburg50
招募中
4 期
CHOLINE-2 - Donepezil Versus Non-drug Treatment in Alzheimer's Disease2024-515038-34-00Assistance Publique Hopitaux De Paris240
已完成
不适用
Choline and Brain Functioning in Postmenopausal WomenMenopauseNCT07264257University of Vermont38
招募中
4 期
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body DementiaNCT07284290Virginia Commonwealth University120
已完成
不适用
The effect of cholinergic enhancement on brain activation in Parkinson*s disease patients with visual hallucinations using fMRI.Parkinson's diseasevisual hallucinations10028037NL-OMON33228eurologie20